| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 21, 2005
Revised on May 17, 2006
Accepted on May 26, 2006
From the Cardiology Division (M.R.M., S.F., N.A., M.N., L.L., T.M., A.R.), Beth Israel Deaconess Medical Center; and Division of Cardiology (M.S.-C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; Medical Research Center Clinical Sciences Center (S.A.C.), Hammersmith Hospital, London, UK; and Cardiovascular Research Group (G.M., G.B.), School of Pharmacy, The University of Reading Whiteknights, Berkshire, UK.
* To whom correspondence should be addressed. E-mail: arosenzw{at}bidmc.harvard.edu.
Myostatin is a highly conserved, potent negative regulator of skeletal muscle hypertrophy in many species, from rodents to humans, although its mechanisms of action are incompletely understood. Transcript profiling of hearts from a genetic model of cardiac hypertrophy revealed dramatic upregulation of myostatin, not previously recognized to play a role in the heart. Here we show that myostatin abrogates the cardiomyocyte growth response to phenylephrine in vitro through inhibition of p38 and the serine-threonine kinase Akt, a critical determinant of cell size in many species from drosophila to mammals. Evaluation of male myostatin-null mice revealed that their cardiomyocytes and hearts overall were slightly smaller at baseline than littermate controls but exhibited more exuberant growth in response to chronic phenylephrine infusion. The increased cardiac growth in myostatin-null mice corresponded with increased p38 phosphorylation and Akt activation in vivo after phenylephrine treatment. Together, these data demonstrate that myostatin is dynamically regulated in the heart and acts more broadly than previously appreciated to regulate growth of multiple types of striated muscle.
This article has been cited by other articles:
![]() |
M. R. Morissette, S. A. Cook, C. Buranasombati, M. A. Rosenberg, and A. Rosenzweig Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt Am J Physiol Cell Physiol, November 1, 2009; 297(5): 1124 - 1132. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Oshima, N. Ouchi, M. Shimano, D. R. Pimentel, K. N. Papanicolaou, K. D. Panse, K. Tsuchida, E. Lara-Pezzi, S.-J. Lee, and K. Walsh Activin A and Follistatin-Like 3 Determine the Susceptibility of Heart to Ischemic Injury Circulation, October 20, 2009; 120(16): 1606 - 1615. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Rodgers, J. P. Interlichia, D. K. Garikipati, R. Mamidi, M. Chandra, O. L. Nelson, C. E. Murry, and L. F. Santana Myostatin represses physiological hypertrophy of the heart and excitation\#8211;contraction coupling J. Physiol., October 15, 2009; 587(20): 4873 - 4886. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Dubach, S. Das, A. Rosenzweig, and H. A. Clark Visualizing sodium dynamics in isolated cardiomyocytes using fluorescent nanosensors PNAS, September 22, 2009; 106(38): 16145 - 16150. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. U. Trendelenburg, A. Meyer, D. Rohner, J. Boyle, S. Hatakeyama, and D. J. Glass Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1258 - C1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Welle, K. Burgess, and S. Mehta Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice Am J Physiol Endocrinol Metab, March 1, 2009; 296(3): E567 - E572. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ciarmela, E. Wiater, S. M. Smith, and W. Vale Presence, Actions, and Regulation of Myostatin in Rat Uterus and Myometrial Cells Endocrinology, February 1, 2009; 150(2): 906 - 914. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lara-Pezzi, L. E. Felkin, E. J. Birks, P. Sarathchandra, K. D. Panse, R. George, J. L. Hall, M. H. Yacoub, N. Rosenthal, and P. J. R. Barton Expression of Follistatin-Related Genes Is Altered in Heart Failure Endocrinology, November 1, 2008; 149(11): 5822 - 5827. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Rodgers and D. K. Garikipati Clinical, Agricultural, and Evolutionary Biology of Myostatin: A Comparative Review Endocr. Rev., August 1, 2008; 29(5): 513 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. B. Li, H. D. Kollias, and K. R. Wagner Myostatin Directly Regulates Skeletal Muscle Fibrosis J. Biol. Chem., July 11, 2008; 283(28): 19371 - 19378. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Oshima, N. Ouchi, K. Sato, Y. Izumiya, D. R. Pimentel, and K. Walsh Follistatin-Like 1 Is an Akt-Regulated Cardioprotective Factor That Is Secreted by the Heart Circulation, June 17, 2008; 117(24): 3099 - 3108. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sandri Signaling in Muscle Atrophy and Hypertrophy Physiology, June 1, 2008; 23(3): 160 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-W. Wang, H. Chang, P. Kuan, and K.-G. Shyu Angiotensin II activates myostatin expression in cultured rat neonatal cardiomyocytes via p38 MAP kinase and myocyte enhance factor 2 pathway J. Endocrinol., April 1, 2008; 197(1): 85 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Murtaza, H.-X. Wang, X. Feng, N. Alenina, M. Bader, B. S. Prabhakar, and P.-F. Li Down-regulation of Catalase and Oxidative Modification of Protein Kinase CK2 Lead to the Failure of Apoptosis Repressor with Caspase Recruitment Domain to Inhibit Cardiomyocyte Hypertrophy J. Biol. Chem., March 7, 2008; 283(10): 5996 - 6004. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wu, H. Kausar, P. Johnson, D. E. Montoya-Durango, M. Merchant, and M. J. Rane Hsp27 Regulates Akt Activation and Polymorphonuclear Leukocyte Apoptosis by Scaffolding MK2 to Akt Signal Complex J. Biol. Chem., July 27, 2007; 282(30): 21598 - 21608. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N Artaza, S. Reisz-Porszasz, J. S Dow, R. A Kloner, J. Tsao, S. Bhasin, and N. F Gonzalez-Cadavid Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse J. Endocrinol., July 1, 2007; 194(1): 63 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. McKoy, K. A. Bicknell, K. Patel, and G. Brooks Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation Cardiovasc Res, May 1, 2007; 74(2): 304 - 312. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Welle, K. Bhatt, C. A. Pinkert, R. Tawil, and C. A. Thornton Muscle growth after postdevelopmental myostatin gene knockout Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E985 - E991. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L885 - L897. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Yang, Y. Zhang, Y. Li, Z. Wu, and D. Zhu Myostatin Induces Cyclin D1 Degradation to Cause Cell Cycle Arrest through a Phosphatidylinositol 3-Kinase/AKT/GSK-3beta Pathway and Is Antagonized by Insulin-like Growth Factor 1 J. Biol. Chem., February 9, 2007; 282(6): 3799 - 3808. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. McMullen, F. Amirahmadi, E. A. Woodcock, M. Schinke-Braun, R. D. Bouwman, K. A. Hewitt, J. P. Mollica, L. Zhang, Y. Zhang, T. Shioi, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110{alpha}) signaling in dilated and hypertrophic cardiomyopathy PNAS, January 9, 2007; 104(2): 612 - 617. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |